Evidence map›Paper›PMID 36973349›Full record

ArticleLeukemia2023

Response to the Comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH) on the 5th edition of the World Health Organization classification of haematolymphoid tumors.

Reiner Siebert, Anna Schuh, German Ott, Ian A Cree, Ming-Qing Du, Judith Ferry, Andreas Hochhaus, Kikkeri N Naresh, Eric Solary, Joseph D Khoury

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Reiner SiebertInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany. reiner.siebert@uni-ulm.de.ORCID 0000-0001-7433-3703
Anna SchuhDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-3938-8490
German OttDepartment of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Ian A CreeInternational Agency for Research on Cancer (IARC), World Health Organization, 25 Avenue Tony Garnier, CS 90627, 69366, Lyon, France.ORCID 0000-0001-5007-9456
Ming-Qing DuDivision of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK.ORCID 0000-0002-1017-5045
Judith FerryDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Andreas HochhausHematology/Oncology, Universitätsklinikum Jena, Jena, Germany.ORCID 0000-0003-0626-0834
Kikkeri N NareshSection of Pathology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0003-3807-3638
Eric SolaryDepartment of Hematology, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France.ORCID 0000-0002-8629-1341
Joseph D KhouryDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0003-2621-3584

Funding

World Health Organization 001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Chromosome AberrationsNeoplasmsCytogenetic AnalysisHumans

Identifiers

PMID36973349
PMCPMC10169644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.